==== Front Genes Dis Genes Dis Genes & Diseases 2352-4820 2352-3042 Chongqing Medical University S2352-3042(22)00009-5 10.1016/j.gendis.2021.12.015 Review Article Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches Huang Yue yue.huang@ncrcnd.org.cn abc∗1 Wei Jun c1 Cooper Antony de Morris Margaret J. c a China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China b Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China c Department of Pharmacology, School of Medical Sciences, Faculty of Medicine & Health, UNSW, Sydney, NSW 2052, Australia d The Garvan Institute of Medical Research, Sydney, NSW 2010, Australia e St Vincent's Clinical School, Faculty of Medicine & Health, and School of Biotechnology and Biomolecular Sciences, Faculty of Science, UNSW, Sydney, NSW 2052, Australia ∗ Corresponding author. No. 119, South Forth Ring West Road, Fengtai District, Beijing 100070, China. Fax: +86 10 5997 5698. yue.huang@ncrcnd.org.cn 1 YH and JW contributed equally to the article. 05 2 2022 5 2023 05 2 2022 10 3 786798 1 2 2021 29 11 2021 22 12 2021 © 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. 2022 Chongqing Medical University https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Parkinson's disease (PD) is the most common neurodegenerative movement disorder in the elderly. As the pathogenesis of PD is still not fully understood, medications with the capacity of halting the disease progression are currently unavailable. The discovery of genes that are causative for, or increase susceptibility to PD is pivotal for the development of novel therapeutic approaches, as they are critical for the onset of PD and the molecular pathways underlying its pathogenesis. By reviewing relevant data, we discuss causative genes, and those associated with PD susceptibility and quantitative traits. Through Gene Ontology database and STRING analysis, we emphasize the roles of inorganic cation transmembrane transport pathways and hypothalamic pituitary thyroid axis, in addition to the established roles of inflammation/oxidative stress and mitochondrial dysfunction in the pathogenesis of PD. It is hoped these insights 1) untangle the clinical complex presentations of PD, 2) reveal the interwoven molecular network leading to PD, and 3) identify critical molecular targets to facilitate novel PD drug discovery, with a view to providing improved consultation and personalized medicine for patients with PD in the future. Keywords Drug discovery Genetics Molecular function Parkinson's disease Quantitative traits ==== Body pmcIntroduction Parkinson's disease (PD) is the second most common age-related neurodegenerative disease worldwide, affecting over ten million people in the world. The prevalence of PD increases with age, affecting 0.1%–0.2% of the population across all ages, 1% of those over 60 years, and the disease costs over 51.9 billion dollars annually.1,2 An increased understanding of this disease is critically important, particularly in those countries with an ageing population. Many recent studies have identified genetic variants associated with PD. This review will focus on the common PD risk genetic loci and single nucleotide polymorphisms (SNPs) identified in European Caucasian and Asian populations and their impacts on the precision medicine of PD. Although the pathogenesis of PD is not yet fully understood, striatal dopamine deficiency due to the degeneration of dopaminergic neurons of the substantia nigra pars compacta has been recognized as a PD hallmark.3,4 The substantia nigra appears depigmented macroscopically due to the death of neuromelanin containing dopaminergic neurons, and there are two distinct microscopic features for the pathological diagnosis of PD: intracellular α-synuclein aggregations and dopaminergic cell degeneration.5,6 α-Synuclein can exist as a small soluble monomer which can form oligomers or larger protein aggregates, that are components of Lewy bodies and Lewy neurites in dopaminergic neurons.6,7 Due to the dopaminergic neuronal dysfunction and cell death, there is insufficient dopamine in the striatum, which affects the initiation of movement,4,5 that in turn accounts for the movement symptoms displayed by patients. Therefore, replacing striatal dopamine through medications such as l-dopa is an effective symptomatic treatment,3,5 but all existing symptomatic therapies for PD (including l-dopa) do not target the underlying molecular mechanisms of the disease, and have little to no impact on disease progression. The clinical presentations of PD are asymmetrical and develop progressively.5 Although the common motor symptoms are bradykinesia, resting tremor, muscle rigidity and postural instability, there are a variety of non-motor presentations including neuropsychiatric symptoms (e.g., depression, anxiety, sleep disorders), autonomic dysfunction (e.g., gastrointestinal symptoms of constipation), as well as sensory symptoms (e.g., olfactory dysfunction), which may present earlier than motor symptoms.8 Other symptoms such as pain, fatigue, weight changes, and dementia can also occur, usually in late stages of PD.7,9 Age is the major risk factor for PD, but risk is also attributed to environmental factors that include dairy products, pesticides, methamphetamine, and brain trauma.10 The genetic component of PD has received more interest following GWAS studies that implicate familial PD genes as risk loci for sporadic PD.11 This builds the foundation of identifying the SNPs and associated genes to advance our understanding of the molecular mechanisms that confer increased risk of PD. PD causative genes The first PD causative mutation was discovered in the SNCA gene in Italian and Greek kindreds in 1997.12 Subsequently, many other PD causative genes were identified from linkage analysis by segregating genes from monogenetic PD-affected families (Table 1). PD causative genes follow either autosomal dominant or recessive inherited patterns, mainly reflecting gain or loss of its correspondent molecular functions respectively.Table 1 PD causative genes. Table 1PARK Gene Loci Protein cellular distribution and function Mutations Inheritance Clinical Phenotypes PARK1 SNCA 4q21-23 α-synuclein17: presynaptic signaling and membrane trafficking.93 A53T, A30P,17,94 A18T, A29S, G46L, H50G, G51A95 AD Young-onset and late-onset hereditary Lewy body PD96 PARK2 PRKN 6q25.2-q27 Parkin RBR E3 ubiquitin protein ligase: regulate the autophagic degradation of mitochondria.54 Deletions of exons 1, 4 and 5, and P113Xfs, R275W, G430D and R33X97 AR Young-onset PD (mean onset of PD at 32 y.o.)98 PARK3(putative) Unknown 2p13 – Not identified AD Late onset idiopathic Lewy body PD.99 PARK4 SNCA 4p22.1 α-synuclein17: presynaptic signaling and membrane trafficking.93 duplication and triplication.18,19 AD Young-onset and late-onset hereditary Lewy body PD96 PARK5(putative) UCHL1 4p13 Ubiquitin C-Terminal Hydrolase L1: processing ubiquitinated proteins and ubiquitin precursors.100 Unconfirmed AD Late onset PD(mean onset of PD at 50 y.o.)100 PARK6 PINK1 1p36.12 PTEN induced kinase 1: mitochondria degradation44 Deletions in exon 1, 5, and 751,97, g.16378G > A, c.1488 + 1G > A51 and W90Xfs97 AR Young-onset (mean age at 31.6 y.o.), slowly progressive levodopa-responsive PD.51 PARK7 DJ-1 1p36.23 Parkinsonism associated deglycase: cell protection from toxic stresses.101 M26I, G78G, R98Q, R98R, D149A, A167A and InsA+120.102 AR Young-onset PD.102 PARK8 LRRK2 12q12 Dardarin: GTPase and kinase.103 G2019S,104 R1441G, R1441 C/H, Y1699C, R1628P, G2385R and I2020T.105 AD Mean onset of PD at 58·1 y.o, hereditary (mutations present in 10% patients) and idiopathic (mutations present in 4% of patients) Lewy body PD.7,33 PARK9 (parkinsonism causative) ATP13A2 1p36.13 Lysosomal type 5 ATPase: maintain intracellular cation homeostasis and neuronal integrity106 Deletion in exon 26, 22-bp duplication (1632_1653dup22), 2-bp insertion (1103insGA),107 1306+5G-A,108 G504R,109 M810R,110 G877R.111 AR Kufor-Rakeb syndrome: early onset idiopathic Parkinsonism associated with mask-like face, rigidity and bradykinesia, spasticity, supranuclear gaze palsy and dementia.112 PARK10(putative) Unknown 1p32 – Unconfirmed AD Late onset PD (mean onset of PD at 65.8 y.o.)113 PARK11(putative) GIGYF2(confronted) 2q37.1 GRB10-interacting GYF protein 2: repressing translation initiation114 Deletion L1230_Q1237del, N478T, H1992R115 AD Late onset idiopathic PD116 PARK12(putative) Unknown Xq21-q25 – Unconfirmed X-linked Late onset PD117 PARK13(putative) HTRA2(confronted) 2p13.1 HtrA Serine Peptidase 2: proteolytic activity and promotes apoptosis118 G399S and A141S119 AD Late onset PD (mean onset of PD at 57.3 y.o.) in German population PARK14 (parkinsonism causative) PLA2G6 22q13.1 Phospholipase A2 Group VI: phospholipid remodeling for cellular membrane homeostasis120 R741Q and R747W121 AR Parkinsonism, dystonia and cognitive decline121 PARK15 (parkinsonism causative) FBXO7 22q12.3 F-box only protein 7: mediating the ubiquitination and proteasomal degradation122 A498Stop, T22M, and splice-site IVS7 + 1G/T123 AR Early onset levodopa-responsive Parkinsonian-pyramidal syndrome124 PARK16(putative) Unknown 1q32 – unconfirmed unconfirmed unconfirmed PARK17 VPS35 16q11.2 VPS35 retromer complex component: vesicle transport and membrane-protein recycling.125,126 A620A127 and P316S126 AD Late onset, hereditary PD (mean onset of PD at 53 y.o.).127 PARK18 EIF4G1 3q26-q28 Eukaryotic translation initiation factor 4 gamma 1: involved in mRNA translation.128 A1205H, A502V, G686C, S1164A and A1197T.129 AD Late onset PD (mean onset of PD at 52–64 y.o. for each mutation). PARK19 DNAJC6 1p31.3 DnaJ Heat Shock Protein Family (Hsp40) Member C6: clathrin-mediated endocytosis (by similarity) Q734X130 Q789X131 and R927G132 AR Juvenile onset or early adult-onset PD132,133 PARK20 SYNJ1 21q22.11 Synaptojanin-1: clathrin-mediated endocytosis (by similarity) R258Q,134,135 R459P136 AR Early onset PD in an Iranian and an Italian population134 PARK21 DNAJC13 3q22.1 DnaJ heat shock protein family (Hsp40) member C13: endosomal membrane regulation.137 A855S138 AD Late onset PD (mean onset of PD at 67 y.o.)138 PARK22 CHCHD2 7p11.2 Coiled-coil-helix-coiled-coil-helix domain containing 2: mitochondrial respiration139 A32T, P34L, and I80V139 AD Early onset PD139 PARK23 VPS13C 15q22.2 Vacuolar protein sorting-associated protein 13C: Maintaining mitochondrial transmembrane potential.131 Truncating mutations131 AR Rapidly progressive PD in Turkish and French population131 PD causative genes with autosomal dominant inherence Although multiple genes have been shown causative for PD (Table 1), two important PD causative genes identified so far are SNCA and LRRK2. SNCA encodes α-synuclein, a major component of pathological hallmark of Lewy bodies in PD,13 while mutations in LRRK2 are the most common indicators of inherited PD.14,15 Over time, more PD causative genes with autosomal dominant inherence were identified (Table 1), but none has overtaken the importance of SNCA or LRRK2 from pathological or genetic perspective, as outlined below. α-Synuclein is a 140 amino acid presynaptic protein with multiple conformations and exists in many oligomeric states in a dynamic equilibrium.16 Mutant α-synuclein changes its conformation making it prone to form aggregates and Lewy bodies. Amongst the SNCA mutations, the missense mutation A53T was hypothesized as disrupting the α helix and extending the β sheet structure.12 In addition to the Greek pedigree, A53T and other missense mutations in SNCA such as A30P and E46K have been identified in over 12 Mediterranean PD families.11 These SNCA missense mutations lead to structural changes in α-synuclein,17 in which A30P and A53T mutations form annular and pore-like protofibrils, and annular and tubular prefibrillar oligomers correspondingly, under electron microscopy, analytical ultracentrifugation and scanning transmission electron microscopy.17 Apart from point mutations, multiplications of the SNCA region lead to correspondingly elevated expression of α-synuclein, and hence cause typical and atypical PD.11,18 The SNCA genomic multiplications occur due to unequal cross-over during either intra-allelic or inter-allelic recombination or both.19 The multiplications appear to associate with early onset of PD,11 e.g., SNCA triplication has been identified as causing dominant early-onset PD.20 The dosage of SNCA multiplications impacts on the severity of PD and dementia presentations19 due to SNCA over-expression, that can increase α-synuclein aggregation and fibril formation. The addition of recombinant α-synuclein fibrils to primary neurons led to the selective decreases in synaptic proteins, progressive impairments in neuronal connectivity and eventually neuron death.21 In addition, inoculation of recombinant α-synuclein fibrils in the striatum of mice led to pathological cell to cell α-synuclein transmission eventually resulting in dopaminergic neuronal loss in the substantia nigra accompanied by motor deficit.22 Thus, pathologic levels of α-synuclein can induce neuronal toxicity. The N-terminal 32 amino acids of human α-synuclein contain cryptic mitochondrial targeting signal, which is important for α-synuclein binding to mitochondrial membrane and allows α-synuclein to be imported into mitochondria.23,24 Mitochondrial accumulation of α-synuclein potentially affects respiratory complex I activity, increases oxidative stress, and leads to neuronal toxicity.23,24 The C-terminus of α-synuclein interacts with the microtubule binding domain of tau, particularly when tau is hyperphosphorylated,25 and facilitates the formation of neuropathological intraneuronal filamentous inclusinons.26,27 Molecular functions of α-synuclein provide further pathophysiological evidence about the critical role of α-synuclein in the pathogenesis of PD. LRRK2 encodes a large 51-exon multi-domain protein of over 2500 amino acids.28 Its multiple roles include participation in vesicle sorting by mediating the endosomal-autophagic pathway and late endosomal membrane trafficking.29, 30, 31 Over 40 missense mutations in LRRK2 have been identified,11 all of them displaying an autosomal dominant PD pattern, of which G2385R variant (rs34778348) confers a risk for people to develop PD in Asia.32 Studies have found the frequency and penetrance of LRRK2 mutations vary significantly among different ethnicities.28 LRRK2 mutations are found in 2% of patients with PD.14 Gly2019Ser is the most common LRRK2 mutation, and is present at high frequencies mainly in amongst North African and Arabs idiopathic and hereditary PD patients at 39% and 36% correspondingly, as well as in Caucasian PD patients,33 but Gly2019Ser is a rare mutation in Asian populations.11 Other studies have also shown that the frequency and penetrance of LRRK2 mutations vary significantly amongst different ethnicities.28 LRRK2-coded protein contains a GTPase core and kinase domain. The GTPase catalytic core regulates its kinase domain.34 LRRK2 phosphorylates endophilin A at S75 which regulates synaptic vesicle endocytosis and EndoA-dependent membrane tubulation.35 LRRK2 also phosphorylates eukaryotic initiation factor 4E-binding protein (4E-BP), which modulates the eIF4E/4E-BP pathway and stimulates eIF4E-mediated protein translation, resulting in attenuation of resistance to oxidative stress and survival of dopaminergic neuron.36 PD associated mutations in LRRK2 increase its kinase activity on endophilin-A leading to initiation of endocytosis,37 and they can also affect protein synthesis, mitochondrial quality control and further influence neuronal viability.38,39 LRRK2 facilitates α-synuclein inclusion formation.40, 41, 42 Either mutant α-synuclein or mutant LRRK2 can block or disrupt mitophagy or delay autophagosome trafficking.43 Convergent mechanisms of LRRK2 and α-synuclein can act on different targets within the autophagy-lysosomal system, thus leading to PD pathogenesis. PD causative genes with AR inherence PD causative genes with AR inherence often occur in PD patients with early onset. Among them, the most common mutations are in PRKN (previously known as PARK2), followed by PINK1,44 and DJ-1,45 accounting for about 18%, 15% and 0.2% of early onset PD respectively.46, 47, 48, 49 Deletions and mutations in PRKN gene are associated with degeneration of pigmented neurons in the substantia nigra, similar to that seen in PD, but without Lewy bodies on brain autopsy.50,51 However, the compound heterozygous PRKN or PINK1 mutations had dopaminergic neuron loss in substantia nigra and the presence of Lewy bodies.50,51 The pathological differences lie in the complete or partial depletion of its molecular functions caused by mutations. PRKN encodes the E3 ubiquitin ligase parkin, and glycosylated α-synuclein is one of the substrates normally ubiquitinated by parkin.52 Therefore, the parkin mutations inhibits the degradation of α-synuclein. Moreover, parkin deficient mice do not show exacerbated α-synuclein aggregation when crossed with A53T mice,53 suggesting strong dominant effects of SNCA. Parkin contributes to mitochondrial degradation along with PINK1 and DJ-1.54 Mutations in these PD-AR genes have been associated with dysfunction in PRKN and PARK1 mediated mitochondrial quality control through processes including mitophagy, transport, biogenesis, fission and fusion.55, 56, 57 Genes associated with PD susceptibility Since 2009, genome wide association studies (GWAS) have opened a new era to identify PD susceptibility genes via comparison between PD and controls. The first European PD GWAS analysis identified two genetic risk loci with 1713 PD cases and 3978 controls and replicated with 3361 cases and 4573 controls.58 The risk loci identified were SNCA and MAPT, containing risk SNPs rs2736990 and rs393152, respectively.58 This study also replicated PARK16 and the SNPs rs823128 as one of the SNPs previously identified in a Japanese cohort.58 However, some genetic regions e.g., MAPT have genetic heterogeneity in different ethnicities, and the PD association with MAPT gene was not replicated in a Japanese population, according to the GWAS study in 2009.59 The meta-analysis performed by the International Parkinson Disease Genomics Consortium in 2011, involved 5 American and European cohorts and over 7 million SNPs, identified up to 11 risk loci and the most significant SNP in each locus.60 Referring to the genes closest to a SNP, these SNPs were: chr1:154,105,678 (SYT11), rs6710823 (ACMSD), rs2102808 (STK39), rs11711441 (MCCC1/LAMP3), chr4:911,311 (GAK), rs11724635 (BST1), rs356219 (SNCA), chr6:32,588,205 (HLA-DRB5), rs1491942 (LRRK2), rs12817488 (CCDC62/HIP1R) and rs2942168 (MAPT).60 Nalls et al's meta-analysis carried in 2014 initiated an expansion in the discovery of PD associated SNPs by involving all the up-to-date PD GWAS data in European population.61 The study involved over 7 million variants from 1000 Genomes Project in over 13,000 cases and over 95,000 controls. There were 26 independent risk genetic loci identified by primary meta-analysis with the GWAS summary statistics.61 In the replication test in a separate sample set using NeuroX genotyping array that includes over 264,000 variants, 22 out of the 26 genetic loci were replicated and 6 novel loci were identified: SIPA1L2, INPP5F, MIR4697, GCH1, VPS13C and DDRGK1.61 A total of 28 independent risk variants (SNPs) for PD across 24 loci were identified in that study.61 There is evidence suggesting interactions between risk loci eg.rs199347 associates with increased expression of NUPL2 and decreased methylation of GPNMB, and rs823118 increases RAB7L1 expression and decreases BUCKS1 expression.61 In 2017, Chang et al's GWAS identified 12 risk loci, one of them being the novel locus: rs9468199.62 They then performed meta-analysis with their GWAS data and recent GWAS data, and identified 35 novel risk loci of which 17 loci could be replicated.62 On the other hand, the GWAS analysis included six East Asian regions, including mainland China, Hong Kong, Taiwan, Singapore, Malaysia, and Korea, also confirming SNCA and LRRK2 as the most significant risk loci, as well as MCCC1, and 14 other loci reported in European studies.63 This finding suggested mutations in SNCA and LRRK2 significantly change corresponding protein functions causing PD, while their non-coding genetic variants lead to subtle changes in protein functions, conferring risk to develop PD. While MAPT is reported to be a PD risk gene in Asian populations, it appears there are different genetic risk variants of MAPT in Asian populations compared to Caucasians.63,64 The 2019 meta-analysis Nalls et al performed included 17 recent GWAS datasets in European populations, involving over 37,000 cases, over 18,000 PD family cases and 1.4 million controls.65 Ninety PD risk SNPs involved in 78 risk loci were identified.65 On the other hand, the meta-analysis of recent GWAS data conducted in 2020 from mainland China, Hong Kong, Taiwan, Singapore, Malaysia and South Korea populations, identified 11 risk loci, of which 9 were previously identified in a European population: PARK16, ITPKB, MCCC1, SNCA, FAM47E-SCARB2, DLG2, LRRK2, RIT2 and FYN.66 There were novel SNPs rs246814 and rs9638616 associated with SV2C and WBSCR17 (GALNT17) genes respectively, in which the SV2C intronic SNP was subsequently replicated in the European cohort, but the WBSCR17 associated variant did not increase PD risk in European populations.66 Thus, these recent studies in Asia show population genetic heterogeneity in certain PD risk genes. However, GWAS studies of PD with Asian populations are still at a relatively early stage, with a limited number of studies. Future studies are needed to explore the genetic risk factors of PD in different ethnic groups and obtain a better understanding of any common or population-specific genetic variants amongst different ancestries. These aims match those of the recently established Global Parkinson's Genetic program (GP2) which seeks to genotype >150,000 volunteers from Africa, Asia, Europe, and the American continent (https://parkinsonsroadmap.org/gp2/). So far, there have been over 90 independent PD risk SNPs identified in European populations, and these could explain 16–36% of the heritable risk of PD depending on prevalence.65 The GWAS PD susceptibility studies have been summarized (Table 2), and replication in different populations is an essential step for susceptibility gene confirmation. However, the high heterogeneity of different genomic constructs in human ethnic groups and low effect of the SNPs could potentially result in them failing to be replicated.61 This resolution of genetic factors could be improved by increasing the sample size.61 PD risk SNPs are typically associated with a small individual risk, but they occur more frequently in the population compared to PD causative mutations, and have substantial cumulative risk.67 These SNPs are only associated with a small PD risk and are not useful independently in making prognosis of an individual under risk to develop PD. A polygenic risk score (PRS) was therefore introduced, which is calculated by accumulating each risk SNPs as parameters.68,69 This allows each individual to receive a PRS and understand their PD genetic susceptibility. Based on the currently identified risk SNPs, the PRS model could predict PD with a sensitivity of 0.628 and a specificity of 0.686.65 Therein, PRS combining information on additional numbers of PD risk SNPs to assess the risk for developing PD is likely the future direction of genetics of PD.Table 2 PD susceptibility loci via GWAS or Meta-GWAS studies. Table 2Timeline Number of risk loci Number of SNP (rs) Number of cases vs. control Population References Discovery stage Replication stage 2009 3 3 1713 vs. 3978 3361 vs. 4573 Caucasian GWAS58 2009 4 23 1078 vs. 2628 612 vs. 14,139 321 vs 1614 Japanese GWAS59 2011 11 11 5333 vs. 12,019 7053 vs. 9007 Caucasian Meta-GWAS60 2014 22 28 13,708 vs. 95,282 5353 vs. 5551 Caucasian Meta-GWAS61 2017 35 44 GWAS: 6476 vs. 302,042 Meta-analysis: 13,000+ vs. 95,000+ 5851 vs. 5866 Caucasian GWAS and meta-GWAS62 2017 73 90 779 vs. 13,227 5125 vs. 17,604 Asian GWAS63 2019 78 90 30,271 vs. 1,014,601 26,035 vs 403,190 Caucasian Meta-GWAS65 2020 11 11 6724 vs. 24,851 58,533 vs 1,871,337 Asian GWAS and meta-GWAS66 Genes associated with PD quantitative traits Compared to PD genetic susceptibility studies aimed at identifying people at risk of developing PD, genetic studies on PD quantitative traits represent another important stream to identify genetic contributions to the disease process and to further distinguish PD risk from variants affecting PD progression, as slowing/stopping progression is a major goal. PD quantitative traits include continuous variables that include onset age, motor and non-motor severity measures. Patients carrying mutant genes with AR inheritance often have a benign disease course, whereas patients carrying SNCA triplication often have more severe disease course compared to patients with SNCA duplication.19 Heterozygous mutations in GBA accounts for 2.3%–17.9% patients with PD, although GBA is usually not considered as a PD gene due to the incomplete penetrance of GBA mutations, and thus GBA mutations are instead frequently viewed as a strong risk factor for PD.70 GBA gene mutations have also been associated with PD symptoms severity, rate of disease progression, and age of onset.70 Some of the PD risk loci have been shown to be associated with the age at onset71 and the progression of PD in Caucasian and in Asian populations.64,72 Furthermore, PRS also indicates contribution to the prognosis for PD progression, which is proven to associate with the motor and cognitive functional decline among PD patients.69 There is evidence suggesting a higher PRS is associated with early PD onset, however, PRS was not shown to associate with amount of α-synuclein in CSF, which might suggest more SNPs are need to be identified and included in the PRS calculation.73 In addition, a GWAS association study with PD progression was first attempted this year to evaluate genomic contribution to the motor and non-motor progression of PD,74 and a genome-wide survival study this year identified a novel synaptic locus increasing the polygenic score of cognitive progression in PD.75 However, apart from large longitudinal prospective PD cohorts required, the input clinical quantitative measures and the algorithm to reflect the clinical progression of PD are also challenges in conducting such GWAS studies to truly reveal genetic factors associated with the progression of PD. Molecular pathways related to PD genetic factors The genes associated with PD risk are predominantly expressed in neurons,65 with some exceptions, e.g., Coetzee et al studied 4 risk loci containing risk SNPs which were shown in non-neuronal cells,26,67 encouraging future studies to investigate the function of SNPs associated with the etiology of PD. Majority of the associated genes of these SNPs are protein coding genes that shared the same biological pathways. There have been 10 biological pathways identified as enriched in these encoded proteins, 4 of which are associated with vacuolar functions, and three involving a known pharmaceutical target, e.g., kinase signaling and calcium transporters.65 According to the Gene Ontology (GO) database,76 the biological pathways of currently identified SNPs were listed and their associated genes belonging to different categories as demonstrated in Figure 1.Figure 1 Bar chart of different categories of the protein functions. The proteins are encoded by the PD risk genes and their functions base on Gene Ontology (GO) database.76 The bar chart is stimulated using Metascape.140 The top 25 of the function categories were included in this chart. Fig. 1 Figure 1 shows that the pathway with the highest P-value for enrichment of PD genes is inorganic cation transmembrane transport, a process whereby inorganic cations are transported across membrane by means of a transporter or pore. This is related to 712 genes, and 17 of them are related to PD, such as LRRK2, RIMS1, etc.76 In the PD risk gene products involved in inorganic cation transmembrane transport, 8 are associated with calcium ion transmembrane transport, which is important for regulation of mitochondrial function. Mitochondrial dysfunction and redox metals, i.e., inorganic substance with 12 genes involved, can cause oxidative stress, which has been shown to contribute to the etiology of PD.77 A recent study showed over-expression of α-synucleins increased Voltage Dependent Ion Channel 3 (VDIC3) permeability for calcium ions resulting in a net influx.78 Another cation, magnesium is also related to PD. Long-term magnesium deficiency leads to loss of dopaminergic neurons, and epidemiological studies show a higher incidence of PD in patients with low magnesium concentrations.79 These studies highlight the importance of inorganic cation imbalance to PD etiology, and as a potential target for therapeutic intervention. By STRING analysis (Fig. 2), PD risk genetic products network shows 105 nodes, of which 32 are hub nodes with connection degrees much greater than the average edge degree of the network which is 2.11.80 Some hub nodes demonstrate prominently abundant connections with other nodes, such as SNCA, LRRK2, MAPT, GBA, VPS13C, DGKQ and NOD2, which are all protein coding genes. Some of these are discussed above (Table 1). DGKQ encodes for diacylglycerol kinase θ protein, and is mainly expressed in the brain, mediating lipid and protein interaction in signal-transducing complexes,81 modulating calcium signalling and synaptic vesicles trafficking at nerve terminals.82 NOD2 encodes nucleotide-binding oligomerization domain-containing protein 2, which are intracellular signalling proteins mediating NF-κB activation and apoptosis.83 Inflammation-derived oxidative stress accelerates the neurodegeneration in nigrostriatal pathway in PD.83Figure 2 Network diagram demonstrates interactions between the risk gene products. The PD risk genetic products network shows 105 nodes and 111 edges. The different colours in the figure indicate different biological processes in which the highlighted genes are involved. Red represents “regulation of peroxidase activity”; Dark blue represents “activated T cell proliferation”; Light green represents “glycosylceramide catabolic process”; Light yellow represents “negative regulation of protein targeting to mitochondrion”; Pink represents “negative regulation of establishment of protein localization to mitochondrion”; Dark green represents “positive regulation of nitric-oxide synthase biosynthetic process”; Light blue represents “negative regulation of amine transport”; Dark yellow represents “response to thyroid hormone”; Purple represents “negative regulation of response to drug”; Brown represents “regulation of cytokine production involved in inflammatory response”.76 The graphic is made using STRING v11.0. Fig. 2 There are 111 edges in this network which is much greater than the expected number of 42, suggesting more interactions than random connections. Each edge represents a common pathway in which the genes products are involved. It demonstrates enrichment in certain biological process networks, such as regulation of peroxidase activity involving α-synuclein and LRRK2. These reflect the molecular pathways relevant to these genes involved in PD. The top 10 pathways with high strength of enrichment are colored in Figure 2, e.g., peroxidase regulation and activated T-cell proliferation. α-Synuclein and LRRK2 are involved in the peroxidase regulation pathway. Glutathione peroxidase has been shown to be protective against oxidative stress in the progression of PD.84 The activated T-cell proliferation pathway involves FYN and SATB1. The expanded terminal effector CD8+ and cytotoxic CD4+ peripheral T cells in PD patients85 suggest T-cells could be a therapeutic target to lessen neurodegeneration in PD. Figure 2 reflects the molecular pathways relevant to these genetic products involved in PD, where reactive oxygen species induced inflammation/oxidative stress and mitochondrial dysfunction have also been shown in GO database analysis (Fig. 1). Interestingly, both analyses show that response to thyroid hormone is related to PD (Figure 1, Figure 2), which indicates that hypothalamic pituitary thyroid axis may play an important role in PD pathogenesis. Research has shown that regulation of thyroid-stimulating hormone and thyroid hormones correlates with the severity of PD.86 These identified pathways correlate with other databases including Reactome, KEGG, BIOCARTA, Pathway Interaction Database, Matrisome project, Signalling Gateway, Sigma Aldrich and SuperArray SABiosciences.87 These databases also suggest pathways such as lipid metabolism, immune response, synaptic transmission, endosomal–lysosomal dysfunction and apoptosis mediated by initiator and executioner caspases.87 Moreover, adaptive and innate immune response, vesicular-mediated transport, and lipid metabolism affected by signalling mechanisms were all associated with PD.87 Recent studies showed that LRRK2 phosphorylates SYNJ1 and DNAJC6 for vesicle endocytosis and recycling.37,88 Other PARK genes encoded proteins such as Parkin, involve AMPA-type glutamate receptor (AMPAR) trafficking.89 Mutations lead to AMPAR trafficking defects which affect synaptic plasticity, and this impacts on information processing leading to PD psychiatric symptoms.8,90 Further studies are required to identify other potential pathways and search for any link with the biological hallmarks of PD. Genetic implications for PD therapy There have been several PD risk genes identified as therapeutic targets. The GBA target treatment focus on its encoded protein glucocerebrosidase, and glucosylceramide synthase inhibitor and ambroxol hydrochloride have already been used in clinical trials, with the latter therapy displaying promising indications.91 Early stage of clinical trials (BIIB094 and DNL201) targeting LRRK2 expression or its kinase activity are underway (NCT03976349 & NCT03710707). There is also evidence suggesting deep brain stimulation therapy is effective in certain monogenic PD patients such as those with LRRK2 p.G2019S or PRKN mutations.87,92 This was not effective in patients with mutations such as SNCA and GBA, possibly due to their associated rapid disease progression.92 The identified genetic factors also contribute to the need to adjust the appropriate dosage of levodopa medication for PD patients. The mutations within genes involved in levodopa metabolism (DDC and COMT), dopamine transportation (DAT) and dopamine signaling (DRD2 and DRD3) greatly affect the required dosage of these medications.87 Unfortunately, we still do not have sufficient insights as to what mechanisms to target in individual patients as we lack a full understanding of the pathways associated with PD. Therefore, identifying the genes with their biological pathway involved in current PD treatment regime is important in providing patients with personalized practice. Conclusion Since the late 20th century, studies have been investigating genetic associations with PD. To date, there have been over 70 genes and their specific SNPs identified to increase PD risk. These genetic risk factors also associate with the type and severity of PD clinical manifestations, age of onset and PD progression. However, those identified so far only represent a small proportion of PD risk genetic factors. Future studies should continue exploring novel loci using advanced genotyping arrays in larger sample sizes. The heterogeneous genomic construct among different populations warrants validation and confirmation for PD susceptibility genes. In addition, characterizing the genomic contributions to the progression and subtypes of PD represents a medical advance poised to facilitate clinical practice in the real world of PD management. This would further increase the accuracy of disease treatment and provide a better management plan for PD patients, to achieve evidence-based, high-quality medicine. Author contributions YH designed the project and critically revised the manuscript; JW drafted the manuscript; MM and AC co-supervised JW and actively participated in the manuscript revision. Conflict of interests The authors declare no conflict of interests. Funding This work is supported by 10.13039/501100001809 National Natural Science Foundation of China (No. NSFC 82071417, YH). AC received grant funding from the Australian government. Peer review under responsibility of Chongqing Medical University. ==== Refs References 1 Tysnes O.B. Storstein A. Epidemiology of Parkinson's disease J Neural Transm (Vienna) 124 8 2017 901 905 28150045 2 Yang W. Hamilton J.L. Kopil C. Current and projected future economic burden of Parkinson's disease in the U.S NPJ Parkinsons Dis 6 2020 15 32665974 3 Poewe W. Seppi K. Tanner C.M. Parkinson disease Nat Rev Dis Prim 3 2017 17013 28332488 4 Kalia L.V. Lang A.E. Parkinson disease in 2015:evolving basic, pathological and clinical concepts in PD Nat Rev Neurol 12 2 2016 65 66 26782330 5 Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects Nat Rev Genet 7 4 2006 306 318 16543934 6 Mor D.E. Ischiropoulos H. The convergence of dopamine and α-synuclein: implications for Parkinson's disease J Exp Neurosci 12 2018 1179069518761360 7 Kalia L.V. Kalia S.K. McLean P.J. Α-Synuclein oligomers and clinical implications for Parkinson disease Ann Neurol 73 2 2013 155 169 23225525 8 Hussein A. Guevara C. Valle P. Non-motor symptoms of Parkinson’s disease: the neurobiology of early psychiatric and cognitive dysfunction Neuroscientist 10738584211011979 2021 10.1177/10738584211011979 Online ahead of print 9 Chaudhuri K.R. Healy D.G. Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol 5 3 2006 235 245 16488379 10 Ascherio A. Schwarzschild M.A. The epidemiology of Parkinson's disease: risk factors and prevention Lancet Neurol 15 12 2016 1257 1272 27751556 11 Lesage S. Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors Hum Mol Genet 18 R1 2009 R48 R59 19297401 12 Polymeropoulos M.H. Lavedan C. Leroy E. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 5321 1997 2045 2047 9197268 13 Spillantini M.G. Schmidt M.L. Lee V.M. Alpha-synuclein in lewy bodies Nature 388 6645 1997 839 840 9278044 14 Ross O.A. Toft M. Whittle A.J. Lrrk2 and Lewy body disease Ann Neurol 59 2 2006 388 393 16437559 15 Giasson B.I. Covy J.P. Bonini N.M. Biochemical and pathological characterization of Lrrk2 Ann Neurol 59 2 2006 315 322 16437584 16 Dehay B. Bourdenx M. Gorry P. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations Lancet Neurol 14 8 2015 855 866 26050140 17 Lashuel H.A. Petre B.M. Wall J. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils J Mol Biol 322 5 2002 1089 1102 12367530 18 Singleton A.B. Farrer M. Johnson J. α-Synuclein locus triplication causes Parkinson's disease Science 302 5646 2003 841 14593171 19 Ross O.A. Braithwaite A.T. Skipper L.M. Genomic investigation of alpha-synuclein multiplication and Parkinsonism Ann Neurol 63 6 2008 743 750 18571778 20 Mata I.F. Shi M. Agarwal P. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level Arch Neurol 67 11 2010 1350 1356 21060011 21 Volpicelli-Daley L.A. Luk K.C. Patel T.P. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death Neuron 72 1 2011 57 71 21982369 22 Luk K.C. Kehm V. Carroll J. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice Science 338 6109 2012 949 953 23161999 23 Devi L. Raghavendran V. Prabhu B.M. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain J Biol Chem 283 14 2008 9089 9100 18245082 24 Liu G. Zhang C. Yin J. Alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity Neurosci Lett 454 3 2009 187 192 19429081 25 Haggerty T. Credle J. Rodriguez O. Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease Eur J Neurosci 33 9 2011 1598 1610 21453448 26 Alim M.A. Hossain M.S. Arima K. Tubulin seeds alpha-synuclein fibril formation J Biol Chem 277 3 2002 2112 2117 11698390 27 Giasson B.I. Forman M.S. Higuchi M. Initiation and synergistic fibrillization of tau and alpha-synuclein Science 300 5619 2003 636 640 12714745 28 Paisán-Ruíz C. Nath P. Washecka N. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls Hum Mutat 29 4 2008 485 490 18213618 29 Alegre-Abarrategui J. Christian H. Lufino M.M. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model Hum Mol Genet 18 21 2009 4022 4034 19640926 30 Dodson M.W. Zhang T. Jiang C. Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning Hum Mol Genet 21 6 2011 1350 1363 22171073 31 Steger M. Tonelli F. Ito G. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases Elife 5 2016 e12813 32 Farrer M.J. Stone J.T. Lin C.H. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia Park Relat Disord 13 2 2007 89 92 33 Healy D.G. Falchi M. O'Sullivan S.S. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol 7 7 2008 583 590 18539534 34 Webber P.J. Smith A.D. Sen S. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities J Mol Biol 412 1 2011 94 110 21806997 35 Matta S. van Kolen K. da Cunha R. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis Neuron 75 6 2012 1008 1021 22998870 36 Imai Y. Gehrke S. Wang H.Q. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila EMBO J 27 18 2008 2432 2443 18701920 37 Cao M. Wu Y. Ashrafi G. Parkinson sac domain mutation in synaptojanin 1 impairs clathrin uncoating at synapses and triggers dystrophic changes in dopaminergic axons Neuron 93 4 2017 882 896 28231468 38 Martin I. Kim J.W. Lee B.D. Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease Cell 157 2 2014 472 485 24725412 39 Kim J.W. Yin X. Jhaldiyal A. Defects in mRNA translation in LRRK2-mutant hiPSC-derived dopaminergic neurons lead to dysregulated calcium homeostasis Cell Stem Cell 27 4 2020 633 645 32846140 40 Huang Y. Song Y.J.C. Murphy K. LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions Acta Neuropathol 116 6 2008 639 646 18936941 41 Guerreiro P.S. Huang Y. Gysbers A. LRRK2 interactions with α-synuclein in Parkinson's disease brains and in cell models J Mol Med (Berl) 91 4 2013 513 522 23183827 42 Volpicelli-Daley L.A. Abdelmotilib H. Liu Z. G2019S-LRRK2 expression augments α-synuclein sequestration into inclusions in neurons J Neurosci 36 28 2016 7415 7427 27413152 43 O'Hara D.M. Pawar G. Kalia S.K. LRRK2 and α-synuclein: distinct or synergistic players in Parkinson's disease? Front Neurosci 14 2020 577 32625052 44 Kawajiri S. Saiki S. Sato S. Genetic mutations and functions of PINK1 Trends Pharmacol Sci 32 10 2011 573 580 21784538 45 Hedrich K. Djarmati A. Schäfer N. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease Neurology 62 3 2004 389 394 14872018 46 Kock N. Müller B. Vieregge P. Role of SCA2 mutations in early- and late-onset dopa-responsive Parkinsonism Ann Neurol 52 2 2002 257 258 12210804 47 Kitada T. Asakawa S. Hattori N. Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism Nature 392 6676 1998 605 608 9560156 48 Ishihara-Paul L. Hulihan M.M. Kachergus J. PINK1 mutations and Parkinsonism Neurology 71 12 2008 896 902 18685134 49 Alcalay R.N. Caccappolo E. Mejia-Santana H. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study Arch Neurol 67 9 2010 1116 1122 20837857 50 Farrer M. Chan P. Chen R. Lewy bodies and Parkinsonism in families with parkin mutations Ann Neurol 50 3 2001 293 300 11558785 51 Samaranch L. Lorenzo-Betancor O. Arbelo J.M. PINK1-linked Parkinsonism is associated with Lewy body pathology Brain 133 Pt 4 2010 1128 1142 20356854 52 Shimura H. Schlossmacher M.G. Hattori N. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease Science 293 5528 2001 263 269 11431533 53 von Coelln R. Thomas B. Andrabi S.A. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy J Neurosci 26 14 2006 3685 3696 16597723 54 Narendra D. Walker J.E. Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to Parkinsonism Cold Spring Harbor Perspect Biol 4 11 2012 a011338 55 Liu J. Liu W. Li R. Mitophagy in Parkinson's disease: from pathogenesis to treatment Cells 8 7 2019 712 31336937 56 Scarffe L.A. Stevens D.A. Dawson V.L. Parkin and PINK1:much more than mitophagy Trends Neurosci 37 6 2014 315 324 24735649 57 Jin S.M. Youle R.J. PINK1- and parkin-mediated mitophagy at a glance J Cell Sci 125 Pt 4 2012 795 799 22448035 58 Simón-Sánchez J. Schulte C. Bras J.M. Genome-wide association study reveals genetic risk underlying Parkinson's disease Nat Genet 41 12 2009 1308 1312 19915575 59 Satake W. Nakabayashi Y. Mizuta I. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease Nat Genet 41 12 2009 1303 1307 19915576 60 Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies Lancet 377 9766 2011 641 649 21292315 61 Nalls M.A. Pankratz N. Lill C.M. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease Nat Genet 46 9 2014 989 993 25064009 62 Chang D. Nalls M.A. Hallgrímsdóttir I.B. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci Nat Genet 49 10 2017 1511 1516 28892059 63 Foo J.N. Tan L.C. Irwan I.D. Genome-wide association study of Parkinson's disease in East Asians Hum Mol Genet 26 1 2017 226 232 28011712 64 Wang G. Huang Y. Chen W. Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease Park Relat Disord 24 2016 89 94 65 Nalls M.A. Blauwendraat C. Vallerga C.L. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies Lancet Neurol 18 12 2019 1091 1102 31701892 66 Foo J.N. Chew E.G.Y. Chung S.J. Identification of risk loci for Parkinson disease in asians and comparison of risk between asians and Europeans: a genome-wide association study JAMA Neurol 77 6 2020 746 754 32310270 67 Coetzee S.G. Pierce S. Brundin P. Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology Sci Rep 6 2016 30509 27461410 68 Euesden J. Lewis C.M. O'Reilly P.F. PRSice: polygenic risk score software Bioinformatics 31 9 2015 1466 1468 25550326 69 Paul K.C. Schulz J. Bronstein J.M. Association of polygenic risk score with cognitive decline and motor progression in Parkinson disease JAMA Neurol 75 3 2018 360 366 29340614 70 Alcalay R.N. Levy O.A. Waters C.C. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations Brain 138 Pt 9 2015 2648 2658 26117366 71 Huang Y. Wang G. Rowe D. SNCA gene, but not MAPT, influences onset age of Parkinson's disease in Chinese and australians BioMed Res Int 2015 2015 135674 25960998 72 Huang Y. Rowe D.B. Halliday G.M. Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease J Parkinsons Dis 1 3 2011 271 276 23939307 73 Ibanez L. Dube U. Saef B. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels BMC Neurol 17 1 2017 198 29141588 74 Tan M.M.X. Lawton M.A. Jabbari E. Genome-wide association studies of cognitive and motor progression in Parkinson's disease Mov Disord 36 2 2021 424 433 33111402 75 Liu G. Peng J. Liao Z. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease Nat Genet 53 6 2021 787 793 33958783 76 Consortium G.O. The Gene Ontology (GO) database and informatics resource Nucleic Acids Res 32 suppl_1 2004 D258 D261 14681407 77 Lan A.P. Chen J. Chai Z.F. The neurotoxicity of iron, copper and cobalt in Parkinson's disease through ROS-mediated mechanisms Biometals 29 4 2016 665 678 27349232 78 Rosencrans W.M. Aguilella V.M. Rostovtseva T.K. αSynuclein regulates mitochondrial calcium transport through the voltage dependent anion channel Biophys J 120 3 2021 194a 79 Yamanaka R. Shindo Y. Oka K. Magnesium is a key player in neuronal maturation and neuropathology Int J Mol Sci 20 14 2019 3439 31336935 80 Das S. Meher P.K. Rai A. Statistical approaches for gene selection, hub gene identification and module interaction in gene co-expression network analysis: an application to aluminum stress in soybean (Glycine max L.) PLoS One 12 1 2017 e0169605 81 Houssa B. Schaap D. van der Wal J. Cloning of a novel human diacylglycerol kinase (DGKtheta) containing three cysteine-rich domains, a proline-rich region, and a pleckstrin homology domain with an overlapping Ras-associating domain J Biol Chem 272 16 1997 10422 10428 9099683 82 Redenšek S. Trošt M. Dolžan V. Genetic determinants of Parkinson's disease: can they help to stratify the patients based on the underlying molecular defect? Front Aging Neurosci 9 2017 20 28239348 83 Ma Q. An X. Li Z. P268S in NOD2 associates with susceptibility to Parkinson's disease in Chinese population Behav Brain Funct 9 2013 19 23651603 84 Gökçe Çokal B. Yurtdaş M. Keskin Güler S. Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson's disease Neurol Sci 38 3 2017 425 431 27900485 85 Wang P. Yao L. Luo M. Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson's disease Cell Discov 7 1 2021 52 34282123 86 Mohammadi S. Dolatshahi M. Rahmani F. Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors J Endocrinol Invest 44 1 2021 1 13 32500445 87 Bandres-Ciga S. Saez-Atienzar S. Kim J.J. Large-scale pathway specific polygenic risk and transcriptomic community network analysis identifies novel functional pathways in Parkinson disease Acta Neuropathol 140 3 2020 341 358 32601912 88 Nguyen M. Krainc D. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease Proc Natl Acad Sci Unit States Am 115 21 2018 5576 5581 89 Cortese G.P. Zhu M. Williams D. Parkin deficiency reduces hippocampal glutamatergic neurotransmission by impairing AMPA receptor endocytosis J Neurosci 36 48 2016 12243 12258 27903732 90 Kessels H.W. Malinow R. Synaptic AMPA receptor plasticity and behavior Neuron 61 3 2009 340 350 19217372 91 Mullin S. Smith L. Lee K. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial JAMA Neurol 77 4 2020 427 434 31930374 92 Kuusimäki T. Korpela J. Pekkonen E. Deep brain stimulation for monogenic Parkinson's disease: a systematic review J Neurol 267 4 2020 883 897 30659355 93 Logan T. Bendor J. Toupin C. Α-Synuclein promotes dilation of the exocytotic fusion pore Nat Neurosci 20 5 2017 681 689 28288128 94 Krüger R. Kuhn W. Müller T. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease Nat Genet 18 2 1998 106 108 9462735 95 Konno T. Ross O.A. Puschmann A. Dickson D.W. Wszolek Z.K. Autosomal dominant Parkinson's disease caused by SNCA duplications Park Relat Disord 22 Suppl 1 2016 S1 S6 96 Mueller J.C. Fuchs J. Hofer A. Multiple regions of alpha-synuclein are associated with Parkinson's disease Ann Neurol 57 4 2005 535 541 15786467 97 Tan M.M.X. Malek N. Lawton M.A. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study Brain 142 9 2019 2828 2844 31324919 98 Fan K. Hu P. Song C. Novel compound heterozygous PRKN variants in a Han-Chinese family with early-onset Parkinson's disease Parkinsons Dis 2019 2019 9024894 31929871 99 Gasser T. Müller-Myhsok B. Wszolek Z.K. A susceptibility locus for Parkinson's disease maps to chromosome 2p13 Nat Genet 18 3 1998 262 265 9500549 100 Leroy E. Boyer R. Auburger G. The ubiquitin pathway in Parkinson's disease Nature 395 6701 1998 451 452 9774100 101 Clements C.M. McNally R.S. Conti B.J. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2 Proc Natl Acad Sci Unit States Am 103 41 2006 15091 15096 102 Abou-Sleiman P.M. Healy D.G. Quinn N. The role of pathogenic DJ-1 mutations in Parkinson's disease Ann Neurol 54 3 2003 283 286 12953260 103 Cookson M.R. Cellular effects of LRRK2 mutations Biochem Soc Trans 40 5 2012 1070 1073 22988867 104 Lill C.M. Genetics of Parkinson's disease Mol Cell Probes 30 6 2016 386 396 27818248 105 Rui Q. Ni H. Li D. The role of LRRK2 in neurodegeneration of Parkinson disease Curr Neuropharmacol 16 9 2018 1348 1357 29473513 106 Schultheis P.J. Hagen T.T. O'Toole K.K. Characterization of the P5 subfamily of P-type transport ATPases in mice Biochem Biophys Res Commun 323 3 2004 731 738 15381061 107 Schneider S.A. Paisan-Ruiz C. Quinn N.P. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation Mov Disord 25 8 2010 979 984 20310007 108 Ramirez A. Heimbach A. Gründemann J. Hereditary Parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase Nat Genet 38 10 2006 1184 1191 16964263 109 di Fonzo A. Chien H.F. Socal M. ATP13A2 missense mutations in juvenile Parkinsonism and young onset Parkinson disease Neurology 68 19 2007 1557 1562 17485642 110 Bras J. Verloes A. Schneider S.A. Mutation of the Parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis Hum Mol Genet 21 12 2012 2646 2650 22388936 111 Santoro L. Breedveld G.J. Manganelli F. Novel ATP13A2 (PARK9) homozygous mutation in a family with marked phenotype variability Neurogenetics 12 1 2011 33 39 20853184 112 Najim al-Din A.S. Wriekat A. Mubaidin A. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: kufor-rakeb syndrome Acta Neurol Scand 89 5 1994 347 352 8085432 113 Hicks A.A. Pétursson H. Jónsson T. A susceptibility gene for late-onset idiopathic Parkinson's disease Ann Neurol 52 5 2002 549 555 12402251 114 Morita M. Ler L.W. Fabian M.R. A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development Mol Cell Biol 32 17 2012 3585 3593 22751931 115 Bras J. Simón-Sánchez J. Federoff M. Lack of replication of association between GIGYF2 variants and Parkinson disease Hum Mol Genet 18 2 2009 341 346 18923002 116 Lautier C. Goldwurm S. Dürr A. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease Am J Hum Genet 82 4 2008 822 833 18358451 117 Pankratz N. Nichols W.C. Uniacke S.K. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations Am J Hum Genet 71 1 2002 124 135 12058349 118 Balakrishnan M.P. Cilenti L. Mashak Z. THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death Am J Physiol Heart Circ Physiol 297 2 2009 H643 H653 19502560 119 Strauss K.M. Martins L.M. Plun-Favreau H. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease Hum Mol Genet 14 15 2005 2099 2111 15961413 120 Larsson P.K. Claesson H.E. Kennedy B.P. Multiple splice variants of the human calcium-independent phospholipase A2 and their effect on enzyme activity J Biol Chem 273 1 1998 207 214 9417066 121 Paisan-Ruiz C. Bhatia K.P. Li A. Characterization of PLA2G6 as a locus for dystonia-Parkinsonism Ann Neurol 65 1 2009 19 23 18570303 122 Chang Y.F. Cheng C.M. Chang L.K. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination Biochem Biophys Res Commun 342 4 2006 1022 1026 16510124 123 di Fonzo A. Dekker M.C.J. Montagna P. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome Neurology 72 3 2009 240 245 19038853 124 Shojaee S. Sina F. Banihosseini S.S. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays Am J Hum Genet 82 6 2008 1375 1384 18513678 125 Braschi E. Goyon V. Zunino R. Vps35 mediates vesicle transport between the mitochondria and peroxisomes Curr Biol 20 14 2010 1310 1315 20619655 126 Vilariño-Güell C. Wider C. Ross O.A. VPS35 mutations in Parkinson disease Am J Hum Genet 89 1 2011 162 167 21763482 127 Zimprich A. Benet-Pagès A. Struhal W. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease Am J Hum Genet 89 1 2011 168 175 21763483 128 Adjibade P. Grenier St-Sauveur V. DDX3 regulates endoplasmic reticulum stress-induced ATF4 expression Sci Rep 7 1 2017 13832 29062139 129 Chartier-Harlin M.C. Dachsel J.C. Vilariño-Güell C. Translation initiator EIF4G1 mutations in familial Parkinson disease Am J Hum Genet 89 3 2011 398 406 21907011 130 Köroğlu Ç. Baysal L. Cetinkaya M. DNAJC6 is responsible for juvenile Parkinsonism with phenotypic variability Park Relat Disord 19 3 2013 320 324 131 Elsayed L.E. Drouet V. Usenko T. A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease Ann Neurol 79 2 2016 335 337 132 Olgiati S. Quadri M. Fang M. DNAJC6 mutations associated with early-onset Parkinson's disease Ann Neurol 79 2 2016 244 256 26528954 133 Edvardson S. Cinnamon Y. Ta-Shma A. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile Parkinsonism PLoS One 7 5 2012 e36458 22563501 134 Krebs C.E. Karkheiran S. Powell J.C. The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures Hum Mutat 34 9 2013 1200 1207 23804563 135 Quadri M. Fang M. Picillo M. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism Hum Mutat 34 9 2013 1208 1215 23804577 136 Kirola L. Behari M. Shishir C. Identification of a novel homozygous mutation Arg459Pro in SYNJ1 gene of an Indian family with autosomal recessive juvenile Parkinsonism Park Relat Disord 31 2016 124 128 137 Freeman C.L. Hesketh G. Seaman M.N. RME-8 coordinates the activity of the WASH complex with the function of the retromer SNX dimer to control endosomal tubulation J Cell Sci 127 Pt 9 2014 2053 2070 24643499 138 Vilariño-Güell C. Rajput A. Milnerwood A.J. DNAJC13 mutations in Parkinson disease Hum Mol Genet 23 7 2014 1794 1801 24218364 139 Jansen I.E. Bras J.M. Lesage S. CHCHD2 and Parkinson's disease Lancet Neurol 14 7 2015 678 679 26067110 140 Zhou Y. Zhou B. Pache L. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets Nat Commun 10 1 2019 1523 30944313